Teleflex (Teleflex) Debt-to-Asset

: 0.26 (As of Dec. 2023)

View and export this data going back to 1994. Start your Free Trial

Teleflex's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $88 Mil. Teleflex's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1,839 Mil. Teleflex's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $7,533 Mil. Teleflex's debt to asset for the quarter that ended in Dec. 2023 was 0.26.

Teleflex Debt-to-Asset Historical Data

The historical data trend for Teleflex's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Teleflex Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

0.32

0.36

0.29

0.26

Teleflex Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Asset																0.26	0.25	0.24	0.29	0.26

Competitive Comparison

For the Medical Instruments & Supplies subindustry, Teleflex's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Teleflex Debt-to-Asset Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Teleflex's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Teleflex's Debt-to-Asset falls into.

Teleflex Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Teleflex's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(87.5	+	1838.872)	/	7532.546
	=	0.26

Teleflex's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(87.5	+	1838.872)	/	7532.546
	=	0.26

Teleflex (NYSE:TFX) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Teleflex Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Teleflex's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Teleflex (Teleflex) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Teleflex Inc (NYSE:TFX) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

T1FX34:Brazil

Address

550 East Swedesford Road, Suite 400, Wayne, PA, USA, 19087

Website

https://www.teleflex.com

Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2022 sales), interventional (16%), anesthesia (14%), surgical (14%), interventional urology (12%), original-equipment manufacturing (10%), and all other (10%). Geographic exposure for the business is primarily in the U.S., which accounts for 60% of revenue, with international markets making up the remainder.

Executives

Liam Kelly	officer: EVP & President, International	IDA BUSINESS AND TECHNOLOGY PARK, DUBLIN ROAD, ATHLONE L2 00000
Thomas E Powell	officer: Senior Vice President & CFO	C/O TOMOTHERAPY INCORPORATED, 1240 DEMING WAY, MADISON WI 53717
Stuart A Randle	director	585 WEST 500 SOUTH, BOUNTIFUL UT 84010
Jaewon Ryu	director	950 N. GLEBE ROAD, SUITE 700, ARLINGTON VA 22203
Neena M Patil	director	JAZZ PHARMACEUTICALS, 3170 PORTER DRIVE, PALO ALTO CA 94304
Andrew A Krakauer	director	CANTEL MEDICAL CORP., 150 CLOVE ROAD, 9TH FLOOR, LITTLE FALLS NJ 07424
Cameron P Hicks	officer: Vice President, Global HR	550 E. SWEDESFORD ROAD, SUITE 400, WAYNE PA 19087
Klasko Stephen K. M.d.	director	155 SOUTH LIMERICK ROAD, LIMERICK PA 19468
Jay White	officer: VP & Pres, Global Commercial	3015 CARRINGTON MILL BLVD., MORRISVILLE NC 27560
Daniel V. Logue	officer: VP, Gen Counsel & Secretary	550 E. SWEDESFORD ROAD, SUITE 400, WAYNE PA 19087
John Deren	officer: VP & Chief Accounting Officer	550 E. SWEDESFORD ROAD, SUITE 400, WAYNE PA 19087
James J Leyden	officer: VP, General Counsel, Secretary	C/O INFRASOURCE SERVICES, INC, 500 WEST DUTTON MILL ROAD, ASTON PA 19014
James Winters	officer: Vice President, Mfg and Supply	550 E. SWEDESFORD ROAD, SUITE 400, WAYNE PA 19087
Mario Wijker	officer: Vice President, QARA	550 E. SWEDESFORD ROAD, SUITE 400, WAYNE PA 19087
Benson Smith	director	C/O ROCHESTER MEDICAL INC, ONE ROCHESTER MEDICAL DDRIVE, STEWARTVILLE MN 55976